Published in Leukemia on June 13, 2016
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr (2017) 0.75
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (2014) 44.23
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol (2013) 32.42
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics (2014) 23.22
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res (2012) 15.41
A stem cell molecular signature. Science (2002) 14.47
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol (2014) 8.13
Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science (2014) 5.25
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol (2012) 5.08
Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (2014) 4.34
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (2007) 3.94
Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol (2006) 3.63
Acute Myeloid Leukemia. N Engl J Med (2015) 2.85
Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol (2014) 2.67
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res (2008) 2.58
A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol (2014) 2.17
Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell (2014) 2.15
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res (2012) 2.04
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
Cancer cell lines for drug discovery and development. Cancer Res (2014) 1.60
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature (2014) 1.47
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol (2012) 1.30
Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood (2002) 1.30
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood (2014) 1.23
The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans (2013) 1.18
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. J Clin Oncol (2010) 1.13
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood (2014) 1.12
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res (2010) 1.11
FusionFinder: a software tool to identify expressed gene fusion candidates from RNA-Seq data. PLoS One (2012) 1.11
New cast for a new era: preclinical cancer drug development revisited. J Clin Invest (2013) 1.11
Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia (2004) 1.05
Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia (2011) 1.04
Update on treatment of light chain amyloidosis. Haematologica (2014) 1.00
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol (2013) 0.95
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia (2015) 0.92
Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer (2014) 0.88
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer (2006) 0.86
Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease. Mol Cancer Ther (2003) 0.86
Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression. Mol Biosyst (2009) 0.85
RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics (2015) 0.85
Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opin Pharmacother (2014) 0.85
Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells. Cell Cycle (2010) 0.85
The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J (2014) 0.83
Epigenetics in the hematologic malignancies. Haematologica (2014) 0.83
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res (2015) 0.83
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. Cancer Res (2015) 0.81
Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer (2014) 0.80
A xenograft model of infant leukaemia reveals a complex MLL translocation. Br J Haematol (2008) 0.79
The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer (2015) 0.77
Comparative drug screening in NUT midline carcinoma. Br J Cancer (2014) 0.82